Brief: Novakand Pharma Board Evaluates Reverse Takeover And Fractalkine Divestment

Novakand Pharma AB

09/10/2025 08:34

Oct 9 (Reuters) - Novakand Pharma AB NOVKAN.ST:

NOVAKAND PHARMA PROVIDES AN UPDATE ON THE ONGOING REVERSE TAKE OVER PROCESS

IS DISCUSSING POTENTIAL REVERSE TAKE OVER WITH SWEDISH UN-LISTED GROWTH COMPANIES AIMING TO BE LISTED AT NASDAQ FIRST NORTH AND ARE BOTH IN AND OUTSIDE LIFE SCIENCE SECTOR

BOARD EMPHASIZES THAT CURRENTLY THERE IS NO GUARANTEE THAT A DIVESTMENT OR TRANSFER WILL OCCUR

ASSESSMENT IS THAT ACQUIRER WILL NOT BE BIG PHARMA, BUT RATHER SMALLER CO AND THAT ANY PURCHASE PRICE WOULD LIKELY BE LIMITED

BOARD EVALUATES REVERSE TAKEOVER AND FRACTALKINE DIVESTMENT

BOARD MAY RECOMMEND DE-LISTING AND LIQUIDATION

Source text: ID:nMFN9jrLBr

Further company coverage: NOVKAN.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))